Top Story

Envisia initiates phase 2a clinical trial for glaucoma treatment

January 29, 2015

Envisia Therapeutics initiated a phase 2a clinical trial to investigate the safety and tolerability of ENV515 in glaucoma patients, according to a press release.

ENV515 is a biodegradable particle replication in non-wetting templates (PRINT) formulation of travoprost and may reduce IOP for up to 6 months, the release said.

Perspectives on Glaucoma

Visual field preserved significantly longer in patients treated with latanoprost

January 29, 2015
Open-angle glaucoma patients who lowered their intraocular pressure with latanoprost demonstrated more visual field preservation than a placebo group, researchers…
Breaking News

University of Colorado, Mile High Ophthalmics enter licensing agreement for capsulorrhexis device

January 29, 2015
The University of Colorado and Mile High Ophthalmics have entered into a licensing agreement for the Verus capsulorrhexis device, according to a press release from the…
thumbnail for video 4012857521001 Meeting News CoverageVideo

VIDEO: Numerous platforms improving anterior segment imaging

January 29, 2015
WAILEA, Hawaii – At Hawaiian Eye 2015, Roxana Ursea, MD, discusses current and future anterior segment imaging modalities and their role in diagnosing and treating…
More News Headlines »

CooperVision appoints Orsborn VP of global professional, clinical affairs

January 29, 2015
Gary Orsborn, OD, MS, FAAO, FBCLA, has been named vice president of global professional and clinical affairs for…
More »
thumbnail for video 3980253849001

BLOG: Inform, educate, engage

January 12, 2015
In his video blog, social media expert Agustin L. Gonzalez, OD, FAAO, says that optometrists should remind their…
More »
Meeting News Coverage Video
thumbnail for video 4013322053001

VIDEO: Implementing femtosecond laser into hospital setting creates unique challenges

January 28, 2015
WAILEA, Hawaii – At Hawaiian Eye 2015, Rajesh K. Rajpal, MD, discusses the experience of incorporating femtosecond…
More »